Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Glutamatergic Neurometabolite Levels in Patients With Ultra-Treatment-Resistant Schizophrenia: A Cross-Sectional 3T Proton Magnetic Resonance Spectroscopy Study
Yusuke Iwata, Shinichiro Nakajima, Eric Plitman, et al.
Biological Psychiatry (2018) Vol. 85, Iss. 7, pp. 596-605
Closed Access | Times Cited: 111

Showing 1-25 of 111 citing articles:

Advances in multimodal data fusion in neuroimaging: Overview, challenges, and novel orientation
Yudong Zhang, Zhengchao Dong, Shuihua Wang‎, et al.
Information Fusion (2020) Vol. 64, pp. 149-187
Open Access | Times Cited: 355
Candidate biomarkers in psychiatric disorders: state of the field
Anissa Abi‐Dargham, Scott J. Moeller, Farzana Ali, et al.
World Psychiatry (2023) Vol. 22, Iss. 2, pp. 236-262
Open Access | Times Cited: 156
Glutamatergic and GABAergic metabolite levels in schizophrenia-spectrum disorders: a meta-analysis of 1H-magnetic resonance spectroscopy studies
Tomomi Nakahara, Sakiko Tsugawa, Yoshihiro Noda, et al.
Molecular Psychiatry (2021) Vol. 27, Iss. 1, pp. 744-757
Closed Access | Times Cited: 105
Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment
Masataka Wada, Yoshihiro Noda, Yusuke Iwata, et al.
Molecular Psychiatry (2022) Vol. 27, Iss. 7, pp. 2950-2967
Closed Access | Times Cited: 74
Association of Age, Antipsychotic Medication, and Symptom Severity in Schizophrenia With Proton Magnetic Resonance Spectroscopy Brain Glutamate Level
Kate Merritt, Philip McGuire, Alice Egerton, et al.
JAMA Psychiatry (2021) Vol. 78, Iss. 6, pp. 667-667
Open Access | Times Cited: 97
Glutamate in schizophrenia: Neurodevelopmental perspectives and drug development
Alice Egerton, Anthony A. Grace, James Stone, et al.
Schizophrenia Research (2020) Vol. 223, pp. 59-70
Open Access | Times Cited: 83
Dopamine and Glutamate in Antipsychotic-Responsive Compared With Antipsychotic-Nonresponsive Psychosis: A Multicenter Positron Emission Tomography and Magnetic Resonance Spectroscopy Study (STRATA)
Alice Egerton, Anna Murphy, J Donocik, et al.
Schizophrenia Bulletin (2020) Vol. 47, Iss. 2, pp. 505-516
Open Access | Times Cited: 78
A Selective Review of the Excitatory-Inhibitory Imbalance in Schizophrenia: Underlying Biology, Genetics, Microcircuits, and Symptoms
Yi Liu, Pan Ouyang, Yingjun Zheng, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 75
Variability and magnitude of brain glutamate levels in schizophrenia: a meta and mega-analysis
Kate Merritt, Robert A. McCutcheon, André Alemán, et al.
Molecular Psychiatry (2023) Vol. 28, Iss. 5, pp. 2039-2048
Open Access | Times Cited: 37
Insulin effects on core neurotransmitter pathways involved in schizophrenia neurobiology: a meta-analysis of preclinical studies. Implications for the treatment
Andrea de Bartolomeis, Giuseppe De Simone, Michele De Prisco, et al.
Molecular Psychiatry (2023) Vol. 28, Iss. 7, pp. 2811-2825
Open Access | Times Cited: 23
Neuroimaging Heterogeneity in Psychosis: Neurobiological Underpinnings and Opportunities for Prognostic and Therapeutic Innovation
Aristotle N. Voineskos, Grace Jacobs, Stephanie H. Ameis
Biological Psychiatry (2019) Vol. 88, Iss. 1, pp. 95-102
Open Access | Times Cited: 57
Treatment response after 6 and 26 weeks is related to baseline glutamate and GABA levels in antipsychotic-naïve patients with psychosis
Kirsten Borup Bojesen, Bjørn H. Ebdrup, Kasper Jessen, et al.
Psychological Medicine (2019) Vol. 50, Iss. 13, pp. 2182-2193
Open Access | Times Cited: 55
Levels of glutamatergic neurometabolites in patients with severe treatment-resistant schizophrenia: a proton magnetic resonance spectroscopy study
Ryosuke Tarumi, Sakiko Tsugawa, Yoshihiro Noda, et al.
Neuropsychopharmacology (2019) Vol. 45, Iss. 4, pp. 632-640
Open Access | Times Cited: 55
Changes in Brain Glutamate on Switching to Clozapine in Treatment-Resistant Schizophrenia
Grant McQueen, Kyra-Verena Sendt, Amy Gillespie, et al.
Schizophrenia Bulletin (2020) Vol. 47, Iss. 3, pp. 662-671
Open Access | Times Cited: 55
Exploring causal mechanisms of psychosis risk
Dominic Oliver, Edward Chesney, Alexis E. Cullen, et al.
Neuroscience & Biobehavioral Reviews (2024) Vol. 162, pp. 105699-105699
Open Access | Times Cited: 7
Treatment resistant schizophrenia – review and a call to action
John Lally, Fiona Gaughran
Irish Journal of Psychological Medicine (2018) Vol. 36, Iss. 4, pp. 279-291
Open Access | Times Cited: 51
A meta-analysis of transcranial direct current stimulation for schizophrenia: “Is more better?”
Julia Kim, Yusuke Iwata, Eric Plitman, et al.
Journal of Psychiatric Research (2018) Vol. 110, pp. 117-126
Closed Access | Times Cited: 51
Hypofunctional Dopamine Uptake and Antipsychotic Treatment-Resistant Schizophrenia
Davide Amato, Anna Kruyer, Anne‐Noël Samaha, et al.
Frontiers in Psychiatry (2019) Vol. 10
Open Access | Times Cited: 44
Clozapine response trajectories and predictors of non-response in treatment-resistant schizophrenia: a chart review study
Parita Shah, Yusuke Iwata, Eric E. Brown, et al.
European Archives of Psychiatry and Clinical Neuroscience (2019) Vol. 270, Iss. 1, pp. 11-22
Closed Access | Times Cited: 43
Characteristics and definitions of ultra-treatment-resistant schizophrenia – A systematic review and meta-analysis
Mattia Campana, Peter Falkai, Dan Siskind, et al.
Schizophrenia Research (2021) Vol. 228, pp. 218-226
Open Access | Times Cited: 37
Medial Prefrontal Cortex Glutamate Is Reduced in Schizophrenia and Moderated by Measurement Quality: A Meta-analysis of Proton Magnetic Resonance Spectroscopy Studies
Jason Smucny, Cameron S. Carter, Richard J. Maddock
Biological Psychiatry (2021) Vol. 90, Iss. 9, pp. 643-651
Open Access | Times Cited: 34
Neurofunctional correlates of glutamate and GABA imbalance in psychosis: A systematic review
Uzma Zahid, Ellis Chika Onwordi, Emily Hedges, et al.
Neuroscience & Biobehavioral Reviews (2022) Vol. 144, pp. 105010-105010
Open Access | Times Cited: 23
Multimodal evidence of mediodorsal thalamus-prefrontal circuit dysfunctions in clinical high-risk for psychosis: findings from a combined 7T fMRI, MRSI and sleep Hd-EEG study
Ahmadreza Keihani, Francesco Donati, Sabine A. Janssen, et al.
Molecular Psychiatry (2025)
Closed Access
Associations of Neuromelanin in the Substantia Nigra with Antipsychotic Response in Schizophrenia
Shinichiro Nakajima, Ryosuke Tarumi, Shiori Honda, et al.
Research Square (Research Square) (2025)
Closed Access
Glutamatergic neurometabolites and cortical thickness in treatment-resistant schizophrenia: Implications for glutamate-mediated excitotoxicity
Parita Shah, Eric Plitman, Yusuke Iwata, et al.
Journal of Psychiatric Research (2020) Vol. 124, pp. 151-158
Closed Access | Times Cited: 38
Page 1 - Next Page

Scroll to top